Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.
Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.